MASHINIi

Lifeward Ltd..

LFWD.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Lifeward Ltd., formerly known as Precision Medicine Group, Inc., is a biopharmaceutical company focused on discovering and developing gene therapies for neuromuscular diseases. The company's pipeline includes treatments for Duchenne muscular dystrophy (DMD) and other related conditions. Lifeward aim...Show More

Ethical Profile

Mixed.

Lifeward Ltd. (LFWD.US) shows a mixed ethical record. The company's ReWalk 7 exoskeleton, FDA-cleared to help paralyzed individuals walk, gained significant access with a major U.S. health insurer's approval and a legal precedent for Medicare reimbursement. However, reports suggest a $2.9 million legal claim linked to a ReWalk malfunction. Only 18.3% of shareholders supported executive compensation, indicating potential dissatisfaction. Transparency is also limited regarding product price accessibility, ethical sourcing, and environmental practices, with insufficient public data available for a full assessment.

Value Scores

Better Health for All-40
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business30
-100100
Kind to Animals0
-100100
No War, No Weapons-50
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

-40

Lifeward's core business is focused on developing gene therapies for neuromuscular diseases and its ReWalk exoskeleton product is designed to help paralyzed individuals stand, walk, and navigate.

1
Clinical studies demonstrate natural gait and functional walking speed, with potential for secondary health benefits such as reduced pain, spasticity, improved bowel/urinary function, reduced hospitalizations, medication dependence, and emotional/psychosocial benefits.
2
The company's products are entirely devoted to health improvement. However, clinical studies noted some mild to moderate adverse effects like skin abrasions, lightheadedness, and edema, and a legal claim for $2.9 million in damages related to a ReWalk malfunction was mentioned.
3
Reimbursement for the exoskeleton is a key factor, with no uniform policy, and the company pursues reimbursement from various payors, indicating that affordability is a challenge.
4
The company's prospectus details potential risks including market acceptance, reimbursement, competition, and regulatory hurdles.
5
Lifeward mentions significant R&D investment, including development of ReWalk-Q for quadriplegics and future products, with funding from the BIRD Foundation and OCS.
6
The company provides training programs for healthcare providers and engages in community education programs.
7
Clinical studies also mention potential emotional and psychosocial benefits from the use of their products.
8

Fair Money & Economic Opportunity

0

No evidence available to assess Lifeward Ltd. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No specific, quantitative data points were found across the provided articles to assess Lifeward Ltd. against any of the Fair Pay & Worker Respect KPIs. While executive compensation details were mentioned, median employee compensation was not available, preventing the calculation of the CEO median pay ratio.

1
Information regarding living wage coverage, collective bargaining, safety incident rates, pay equity, worker engagement, turnover, labor violations, insecure contracts, or health insurance coverage was not provided.
2

Fair Trade & Ethical Sourcing

0

No evidence available to assess Lifeward Ltd. on Fair Trade & Ethical Sourcing.

Honest & Fair Business

30

Lifeward Ltd.'s consolidated financial statements are audited by Kost, Forer, Gabbay and Kasierer, a member of Ernst & Young Global Limited, indicating 100% audit coverage of the company's financials.

1
The company has policies prohibiting corrupt payments by employees and mandates compliance with anti-bribery laws, including the FCPA and UK Bribery Act.
2
Its financial statements are independently audited by a registered public accounting firm, serving as third-party verification.
3

Kind to Animals

0

No evidence available to assess Lifeward Ltd. on Kind to Animals.

No War, No Weapons

-50

Lifeward Ltd.'s subsidiary, ReWalk Robotics Ltd., is taking measures consistent with the OECD Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High-Risk Areas, indicating it follows enhanced humanitarian procurement standards.

1
ReWalk conducts annual human rights due diligence in high-risk regions by requesting relevant suppliers to complete the Conflict-Free Smelter Initiative’s (CFSI) Conflict Minerals Reporting Template.
2
The company is committed to respecting human rights and the environment in accordance with applicable laws and regulations, referencing UN Guiding Principles in its policy.
3
For 2024, Lifeward identified 17 suppliers for conflict minerals, with 14 (82%) responding, but the report concludes that conflict minerals may have originated in the Democratic Republic of Congo or other covered countries and may not be entirely from recycled or scrap sources.
4
ReWalk performs annual partner reviews by encouraging suppliers to use CFSI-validated conflict-free smelters and refiners, but no substantive action or divestment is explicitly stated.
5
ReWalk encourages suppliers and external parties to contact them to report suspected abuse, which serves as a basic ethical red line for reporting.
6

Planet-Friendly Business

0

No evidence available to assess Lifeward Ltd. on Planet-Friendly Business.

Respect for Cultures & Communities

0

There is no explicit evidence in the provided articles to assess Lifeward Ltd. against the specified KPIs for 'Respect for Cultures & Communities'. The articles primarily focus on financial performance, corporate filings, product details, and general company operations. While a conflict minerals policy mentions a grievance procedure for stakeholders, it is specific to conflict minerals and does not provide the broad community coverage or quantitative data required by the KPI.

1
No other specific, measurable data points align with the quantitative thresholds or definitions of the KPIs, such as the number of partnerships with indigenous or local community groups, percentage of revenue reinvested locally, or cultural impact assessment protocols.

Safe & Smart Tech

0

No evidence available to assess Lifeward Ltd. on Safe & Smart Tech.

Zero Waste & Sustainable Products

0

No specific, concrete evidence was found in the provided articles to assess Lifeward Ltd. against any of the Key Performance Indicators for the 'Zero Waste & Sustainable Products' ethical value. The articles primarily contain financial information, corporate announcements, or are placeholder content

1
, and do not provide data on waste diversion, product recyclability, packaging sustainability, or other related metrics.
2
Mentions of product warranty or regulatory requirements for hazardous materials do not constitute evidence for the specific KPIs in this rubric.
3

Own Lifeward Ltd.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.